Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
University of California-Davis
mi
from
Sacramento, CA
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
University of California, San Diego
mi
from
San Diego, CA
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
University of California at San Francisco
mi
from
San Francisco, CA
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
Mayo Clinic
mi
from
Jacksonville, FL
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
Northwestern University Med School
mi
from
Chicago, IL
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
Northwestern University Med School
mi
from
Chicago, IL
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
Massachusetts General Hospital
mi
from
Boston, MA
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
The Mayo Clinic
mi
from
Rochester, MN
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
Mount Sinai Medical Center, NY
mi
from
New York, NY
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
Mount Sinai Medical Center, NY
mi
from
New York, NY
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
New York-Presbyterian Hospital
mi
from
New York, NY
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
New York-Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
Oregon Health and Sciences University
mi
from
Portland, OR
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
Albert Einstein Medical Center
mi
from
Philadelphia, PA
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
Albert Einstein Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
Medical University of South Carolina
mi
from
Charleston, SC
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
UT Southwestern Medical Center
mi
from
Dallas, TX
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
Baylor University Medical Center
mi
from
Dallas, TX
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated:  10/11/2017
University of Washington Medical Center
mi
from
Seattle, WA
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
Status: Enrolling
Updated: 10/11/2017
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Status: Enrolling
Updated:  10/12/2017
Huntington Memorial Hospital
mi
from
Pasadena, CA
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Status: Enrolling
Updated: 10/12/2017
Huntington Memorial Hospital
mi
from
Pasadena, CA
Click here to add this to my saved trials
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Status: Enrolling
Updated:  10/12/2017
JFK Medical center
mi
from
Lake Worth, FL
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Status: Enrolling
Updated: 10/12/2017
JFK Medical center
mi
from
Lake Worth, FL
Click here to add this to my saved trials
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Status: Enrolling
Updated:  10/12/2017
Baptist Health South Florida
mi
from
Miami, FL
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Status: Enrolling
Updated: 10/12/2017
Baptist Health South Florida
mi
from
Miami, FL
Click here to add this to my saved trials
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Status: Enrolling
Updated:  10/12/2017
West Suburban Hospital
mi
from
Elmwood Park, IL
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Status: Enrolling
Updated: 10/12/2017
West Suburban Hospital
mi
from
Elmwood Park, IL
Click here to add this to my saved trials
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Status: Enrolling
Updated:  10/12/2017
Hillcrest Medical Center
mi
from
Tulsa, OK
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Status: Enrolling
Updated: 10/12/2017
Hillcrest Medical Center
mi
from
Tulsa, OK
Click here to add this to my saved trials
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Status: Enrolling
Updated:  10/12/2017
Drexel University
mi
from
Philadelphia, PA
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Status: Enrolling
Updated: 10/12/2017
Drexel University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Status: Enrolling
Updated:  10/12/2017
Dr. Omar Kudsi
mi
from
Brockton, MA
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Status: Enrolling
Updated: 10/12/2017
Dr. Omar Kudsi
mi
from
Brockton, MA
Click here to add this to my saved trials
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Status: Enrolling
Updated:  10/12/2017
Athens Medical center
mi
from
Marousi,
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy
Status: Enrolling
Updated: 10/12/2017
Athens Medical center
mi
from
Marousi,
Click here to add this to my saved trials
Gabapentin to Treat Itch in Patients With Liver Disease
Study of Gabapentin for the Pruritus of Cholestasis
Status: Enrolling
Updated:  10/12/2017
Columbia University College of Physicians and Surgeons
mi
from
New York, NY
Gabapentin to Treat Itch in Patients With Liver Disease
Study of Gabapentin for the Pruritus of Cholestasis
Status: Enrolling
Updated: 10/12/2017
Columbia University College of Physicians and Surgeons
mi
from
New York, NY
Click here to add this to my saved trials
Transvaginal Appendectomy
Transvaginal Appendectomy
Status: Enrolling
Updated:  10/13/2017
Yale-New Haven Hospital
mi
from
New Haven, CT
Transvaginal Appendectomy
Transvaginal Appendectomy
Status: Enrolling
Updated: 10/13/2017
Yale-New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Boston, MA
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Charleston, SC
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Richmond, VA
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Concord, CA
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Concord, CA
Click here to add this to my saved trials
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Chevy Chase, MD
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Great Neck, NY
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Great Neck, NY
Click here to add this to my saved trials
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Chattanooga, TN
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
San Antonio, TX
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Milwaukee, WI
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Randwick,
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Randwick,
Click here to add this to my saved trials
Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D
An Open-Label Study Evaluating the Impact of Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Twice Daily on Nutritional Status in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated:  10/16/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D
An Open-Label Study Evaluating the Impact of Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Twice Daily on Nutritional Status in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated: 10/16/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Prevention of Recurrent Hepatitis B After Liver Transplantation
Prevention of Recurrent Hepatitis B After Liver Transplantation
Status: Enrolling
Updated:  10/16/2017
University of Michigan
mi
from
Ann Arbor, MI
Prevention of Recurrent Hepatitis B After Liver Transplantation
Prevention of Recurrent Hepatitis B After Liver Transplantation
Status: Enrolling
Updated: 10/16/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
The Passy Muir Swallowing Self Training Device
Passy-Muir Swallowing Self Training Device to Enhance Recovery Post Stroke
Status: Enrolling
Updated:  10/17/2017
James Madison University and Rockingham Memorial Hospital
mi
from
Harrisonburg, VA
The Passy Muir Swallowing Self Training Device
Passy-Muir Swallowing Self Training Device to Enhance Recovery Post Stroke
Status: Enrolling
Updated: 10/17/2017
James Madison University and Rockingham Memorial Hospital
mi
from
Harrisonburg, VA
Click here to add this to my saved trials
Pasireotide LAR in Severe Polycystic Liver Disease
A Randomized, Placebo Controlled Clinical Trial of SOM230 (Pasireotide LAR) In Severe Polycystic Liver Disease
Status: Enrolling
Updated:  10/18/2017
The Mayo Clinic
mi
from
Rochester, MN
Pasireotide LAR in Severe Polycystic Liver Disease
A Randomized, Placebo Controlled Clinical Trial of SOM230 (Pasireotide LAR) In Severe Polycystic Liver Disease
Status: Enrolling
Updated: 10/18/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
A Phase 1/2a, Open-Label, Parallel, Two-Arm Dose-Escalation Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BAX69 in Subjects With Refractory Ovarian Cancer With Malignant Ascites
Status: Enrolling
Updated:  10/19/2017
University of Miami Miller School of Medicine
mi
from
Miami, FL
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
A Phase 1/2a, Open-Label, Parallel, Two-Arm Dose-Escalation Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BAX69 in Subjects With Refractory Ovarian Cancer With Malignant Ascites
Status: Enrolling
Updated: 10/19/2017
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials